UK-based contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions has established a toll processing agreement with TPI Enterprises to manufacture codeine phosphate (CPO) for sale in the UK market
As part of the agreement, TPI Enterprises, one of three licensed poppy processors in Australia, will produce the narcotic raw material (NRM) at its site in Victoria, while Sterling Pharma Solutions will manufacture the CPO at its Dudley site near Newcastle, UK.
The UK market for CPO is one of the largest in the world, valued at around £20 million per annum. This agreement is the first step in TPI Enterprises’ plan to expand its presence in the UK market.
Kevin Cook, CEO at Sterling Pharma Solutions, commented: “We are delighted to be the partner of choice to support TPI Enterprises during this exciting period of growth. At Sterling, we have developed the infrastructure and capabilities to handle, manufacture and store controlled substances meaning we are well positioned to support this project.”
The agreement provides TPI Enterprises with the means to leverage its unique low cost production advantage to expand its market share in a country that has traditionally high product demand, but very limited supply options.
Jarrod Ritchie, CEO at TPI Enterprises, added: “The agreement will allow us to participate in the UK market and access a new, significant, and from a regulatory basis, previously inaccessible customer base. A combination of Sterling’s API production capability with our low cost raw material supply will greatly enhance customer options in the UK.”
Sterling Pharma Solutions’ site in Dudley, UK, has been in existence for 47 years. The CDMO is the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry.